Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1835 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Foodie Friday: Winter Warm-Up White Bean Soup February 11, 2022 Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma December 17, 2021 SABCS 2021: New Research and Updates in Breast Cancer Treatment and... January 20, 2022 Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... June 7, 2022 Load more HOT NEWS Enfortumab Vedotin Approved for Recurrent Bladder Cancer Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo...
